Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety.
<h4>Background</h4>Lisinopril and losartan manufacturer labels recommend twice-daily dosing (BID) if once-daily (QDay) is insufficient to lower blood pressure (BP).<h4>Methods and results</h4>Retrospective cohort study of patients taking QDay lisinopril and losartan who experienced a dose-doubling (...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Public Library of Science (PLoS)
2020-01-01
|
| Rangatū: | PLoS ONE |
| Urunga tuihono: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0243371&type=printable |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|